4 research outputs found
Morbidité algique aprÚs biopsie du ganglion sentinelle : expérience de l'Institut Jean Godinot
REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Irradiation des cancers de prostate chez l'homme jeune. Résultats d'une série de 174 patients
REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Cardiac Diseases Following Childhood Cancer Treatment:Cohort Study
Backgroundâ
Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD.
Methods and Resultsâ
The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade â„3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5â12.7) and 7·4% (95% CI, 6.2â8.9) when only the CDs of grade â„3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1â48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4â163.0) in those who had received no anthracycline and an HRDâ„30Gy, and 61.5 (95% CI, 19.6â192.8) in those who had received both anthracycline and an HRDâ„30Gy.
Conclusionsâ
Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
</jats:sec
Risk of second bone sarcoma following childhood cancer:role of radiation therapy treatment
Bone sarcoma as a second malignancy is rare but highly fatal. The present knowledge about radiation-absorbed organ doseâresponse is insufficient to predict the risks induced by radiation therapy techniques. The objective of the present study was to assess the treatment-induced risk for bone sarcoma following a childhood cancer and particularly the related risk of radiotherapy. Therefore, a retrospective cohort of 4,171 survivors of a solid childhood cancer treated between 1942 and 1986 in France and Britain has been followed prospectively. We collected detailed information on treatments received during childhood cancer. Additionally, an innovative methodology has been developed to evaluate the doseâresponse relationship between bone sarcoma and radiation dose throughout this cohort. The median follow-up was 26Â years, and 39 patients had developed bone sarcoma. It was found that the overall incidence was 45-fold higher [standardized incidence ratio 44.8, 95Â % confidence interval (CI) 31.0â59.8] than expected from the general population, and the absolute excess risk was 35.1 per 100,000 person-years (95Â % CI 24.0â47.1). The risk of bone sarcoma increased slowly up to a cumulative radiation organ absorbed dose of 15Â Gy [hazard ratio (HR)Â =Â 8.2, 95Â % CI 1.6â42.9] and then strongly increased for higher radiation doses (HR for 30Â Gy or more 117.9, 95Â % CI 36.5â380.6), compared with patients not treated with radiotherapy. A linear model with an excess relative risk per Gy of 1.77 (95Â % CI 0.6213â5.935) provided a close fit to the data. These findings have important therapeutic implications: Lowering the radiation dose to the bones should reduce the incidence of secondary bone sarcomas. Other therapeutic solutions should be preferred to radiotherapy in bone sarcoma-sensitive areas